Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Citi
Chubb
US Department of Justice
Cipla
Merck
McKinsey
Healthtrust
Chinese Patent Office

Generated: June 23, 2018

DrugPatentWatch Database Preview

Estrogens, conjugated; meprobamate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for estrogens, conjugated; meprobamate and what is the scope of estrogens, conjugated; meprobamate freedom to operate?

Estrogens, conjugated; meprobamate
is the generic ingredient in four branded drugs marketed by Medpointe Pharm Hlc and Wyeth Ayerst, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for estrogens, conjugated; meprobamate.
Summary for estrogens, conjugated; meprobamate
US Patents:0
Tradenames:4
Applicants:2
NDAs:2
Drug Master File Entries: 3
DailyMed Link:estrogens, conjugated; meprobamate at DailyMed

US Patents and Regulatory Information for estrogens, conjugated; meprobamate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Ayerst PMB 400 estrogens, conjugated; meprobamate TABLET;ORAL 010971-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medpointe Pharm Hlc MILPREM-200 estrogens, conjugated; meprobamate TABLET;ORAL 011045-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Wyeth Ayerst PMB 200 estrogens, conjugated; meprobamate TABLET;ORAL 010971-005 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medpointe Pharm Hlc MILPREM-400 estrogens, conjugated; meprobamate TABLET;ORAL 011045-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for estrogens, conjugated; meprobamate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Ayerst PMB 200 estrogens, conjugated; meprobamate TABLET;ORAL 010971-005 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Wyeth Ayerst PMB 400 estrogens, conjugated; meprobamate TABLET;ORAL 010971-003 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
QuintilesIMS
Argus Health
Healthtrust
Colorcon
Cipla
Baxter
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.